Intellia Therapeutics (LTS:0JBU) Current Accrued Expense : $32.89 Mil (As of Mar. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Intellia Therapeutics Current Accrued Expense?

Intellia Therapeutics's Current Accrued Expense for the quarter that ended in Mar. 2024 was $32.89 Mil.

Intellia Therapeutics's quarterly Current Accrued Expense increased from Sep. 2023 ($36.97 Mil) to Dec. 2023 ($40.40 Mil) but then declined from Dec. 2023 ($40.40 Mil) to Mar. 2024 ($32.89 Mil).

Intellia Therapeutics's annual Current Accrued Expense increased from Dec. 2021 ($22.95 Mil) to Dec. 2022 ($39.10 Mil) and increased from Dec. 2022 ($39.10 Mil) to Dec. 2023 ($40.40 Mil).

Intellia Therapeutics Current Accrued Expense Historical Data

The historical data trend for Intellia Therapeutics's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Intellia Therapeutics Current Accrued Expense Chart

Intellia Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Current Accrued Expense

Get a 7-Day Free Trial

6.96

14.63

22.95

39.10

40.40

Intellia Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Current Accrued Expense	Get a 7-Day Free Trial															34.76	33.82	36.97	40.40	32.89

Intellia Therapeutics Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.

Intellia Therapeutics Current Accrued Expense Related Terms

Thank you for viewing the detailed overview of Intellia Therapeutics's Current Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Intellia Therapeutics (LTS:0JBU) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Intellia Therapeutics Inc (LTS:0JBU) » Definitions » Current Accrued Expense

Comparable Companies

Traded in Other Exchanges

NTLA:USA 38I:Germany

Address

40 Erie Street, Suite 130, Cambridge, MA, USA, 02139

Website

https://www.intelliatx.com

Intellia Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.

Intellia Therapeutics (LTS:0JBU) Headlines

No Headlines